source
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…BioPharma Dive · 8d ago↗ source
- FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in FoodThe U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader efforts to Make America Healthy Again.fda press · 8d ago↗ source
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…